Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [3] - The company is headquartered in Newton, Massachusetts [3] Product Development - Acumen is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers [3] - The product is currently in an ongoing Phase 2 clinical trial named ALTITUDE-AD, which involves early symptomatic Alzheimer's disease patients [3] - Positive results were reported from the previous Phase 1 trial, INTERCEPT-AD [3] Upcoming Events - Management will participate in a fireside chat at the Stifel Healthcare Conference on November 18, 2024, at 11:30 a.m. ET [1] - The live webcast of the event will be accessible under the Investors tab on the company's website and will be archived for 90 days [2]